SELLAS Life Sciences shares plunged nearly 20% after the biotechnology company priced a $150 million public offering at $13 per share, a discount of around 28% to its previous close. The sell-off followed a sharp rally triggered by positive Phase 3 REGAL trial results for its experimental leukemia vaccine.
SELLAS Life Sciences shares plunge 19%: What triggered the sharp sell-off?
Published ·
Keep reading
Related stories





